First-Line Vitiligo Treatment: Topical JAK Inhibitors and Phototherapy

In "First-Line Vitiligo Treatment: Topical JAK Inhibitors and Phototherapy," our experts compare notes on first-line treatment, from topical JAK inhibitors to phototherapy.

Dr. Desai opens the treatment discussion by describing topical JAK inhibitor therapy as his default first-line option for localized vitiligo, whether the disease is stable or unstable, noting his own involvement in the studies that supported its approval. He calls it the only FDA-approved topical therapy for repigmenting non-segmental vitiligo, with particularly strong efficacy on the head and neck, and cites up-to-two-year data showing some patients continue responding well past six months of treatment. Because the topical is limited to one sixty-gram tube per month in the United States, he caps its use at roughly ten percent body-surface area and layers in other therapies for any remaining involvement.

Combination therapy is central to his approach. He and Dr. Taylor discuss phototherapy and the eczema laser, which Dr. Desai uses routinely alongside topical JAK inhibitors despite label language cautioning against combining topical ruxolitinib with artificial UV light. He argues that widespread data now show narrowband UVB and the eczema laser do not raise skin-cancer risk, though he still limits light exposure for patients with a melanoma history.

Dr. Hamzavi describes a similar first-line preference for JAK inhibitors when access and age allow, followed by calcineurin inhibitors as second line, agents he says are effective but greasier, harder to apply, and more prone to a burning sensation. Ultra-potent topical steroids, used on alternate days, serve as his third line when cost blocks access to the first two options. He counsels patients up front that visible repigmentation can take three to six months, and he adds phototherapy early when possible, since it roughly doubles both the proportion of patients who respond and the speed of repigmentation once treatment begins.

Up next, in "Long-Term Topical Steroid Use in Vitiligo: Safety Concerns," Dr. Hamzavi examines the risks that come with long-term topical steroid use.

This video was supported independently by Pfizer.